Traversa Sergio's Form 4 filing
Relmada Therapeutics, Inc.RLMD · filed Jan 31, 2024
- Accession no.
- 0001213900-24-008560
- Filed
- Jan 31, 2024
- Trade date
- Jan 29-31, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $386.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Traversa SergioCIK 0001565832 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 29, 2024 | Common Stock | PPurchaseAcquired | +31,541 | $3.71F2 | +$117,017.11 | 175,565 | Direct | |
| Jan 30, 2024 | Common Stock | PPurchaseAcquired | +40,999 | $3.90F3 | +$159,896.1 | 216,564 | Direct | |
| Jan 31, 2024 | Common Stock | PPurchaseAcquired | +27,460 | $4.00F4 | +$109,840 | 244,024 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Purchase prices range from $3.69 to $3.75 per share, inclusive.
Referenced by the price of 1 transaction in Table I.
- F3
Purchase prices range from $3.88 to $3.97 per share, inclusive.
Referenced by the price of 1 transaction in Table I.
- F4
Purchase prices range from $3.95 to $4.05 per share, inclusive.
Referenced by the price of 1 transaction in Table I.